KR100975999B1 - 3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도 - Google Patents

3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도 Download PDF

Info

Publication number
KR100975999B1
KR100975999B1 KR1020047015629A KR20047015629A KR100975999B1 KR 100975999 B1 KR100975999 B1 KR 100975999B1 KR 1020047015629 A KR1020047015629 A KR 1020047015629A KR 20047015629 A KR20047015629 A KR 20047015629A KR 100975999 B1 KR100975999 B1 KR 100975999B1
Authority
KR
South Korea
Prior art keywords
formula
compound
alkyl group
group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047015629A
Other languages
English (en)
Korean (ko)
Other versions
KR20040094904A (ko
Inventor
자끄 프롸상
브느와 마라부
프랑 마르구
프레데릭 뿌슈
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20040094904A publication Critical patent/KR20040094904A/ko
Application granted granted Critical
Publication of KR100975999B1 publication Critical patent/KR100975999B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
KR1020047015629A 2002-04-03 2003-04-02 3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도 Expired - Fee Related KR100975999B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR02/04158 2002-04-03
PCT/FR2003/001027 WO2003082874A2 (fr) 2002-04-03 2003-04-02 DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (2)

Publication Number Publication Date
KR20040094904A KR20040094904A (ko) 2004-11-10
KR100975999B1 true KR100975999B1 (ko) 2010-08-17

Family

ID=28052083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047015629A Expired - Fee Related KR100975999B1 (ko) 2002-04-03 2003-04-02 3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도

Country Status (28)

Country Link
US (4) US7235554B2 (cg-RX-API-DMAC10.html)
EP (1) EP1492792B1 (cg-RX-API-DMAC10.html)
JP (2) JP4575670B2 (cg-RX-API-DMAC10.html)
KR (1) KR100975999B1 (cg-RX-API-DMAC10.html)
CN (2) CN100406459C (cg-RX-API-DMAC10.html)
AT (1) ATE321763T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003240930B2 (cg-RX-API-DMAC10.html)
BR (1) BR0309018A (cg-RX-API-DMAC10.html)
CA (1) CA2481460C (cg-RX-API-DMAC10.html)
CY (1) CY1104998T1 (cg-RX-API-DMAC10.html)
DE (1) DE60304327T2 (cg-RX-API-DMAC10.html)
DK (1) DK1492792T3 (cg-RX-API-DMAC10.html)
EA (1) EA007219B1 (cg-RX-API-DMAC10.html)
ES (1) ES2261940T3 (cg-RX-API-DMAC10.html)
FR (1) FR2838124B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20040911B1 (cg-RX-API-DMAC10.html)
IL (2) IL164257A0 (cg-RX-API-DMAC10.html)
IS (1) IS2483B (cg-RX-API-DMAC10.html)
ME (2) MEP23708A (cg-RX-API-DMAC10.html)
MX (1) MXPA04009635A (cg-RX-API-DMAC10.html)
NO (1) NO329426B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ535741A (cg-RX-API-DMAC10.html)
PL (1) PL372617A1 (cg-RX-API-DMAC10.html)
PT (1) PT1492792E (cg-RX-API-DMAC10.html)
RS (1) RS51244B (cg-RX-API-DMAC10.html)
UA (1) UA77273C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003082874A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200407945B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
JP2009504752A (ja) * 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式mGluR1アンタゴニスト
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015552A1 (fr) * 1996-10-08 1998-04-16 Synthelabo DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO1999006406A1 (fr) * 1997-07-30 1999-02-11 Sanofi-Synthelabo DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b] INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2000044384A1 (fr) * 1999-01-26 2000-08-03 Sanofi-Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) * 2001-12-21 2004-12-03 Sanofi Synthelabo DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015552A1 (fr) * 1996-10-08 1998-04-16 Synthelabo DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO1999006406A1 (fr) * 1997-07-30 1999-02-11 Sanofi-Synthelabo DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b] INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2000044384A1 (fr) * 1999-01-26 2000-08-03 Sanofi-Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Also Published As

Publication number Publication date
IS7478A (is) 2004-09-30
AU2003240930B2 (en) 2009-07-30
RS51244B (sr) 2010-12-31
KR20040094904A (ko) 2004-11-10
NO329426B1 (no) 2010-10-18
EP1492792B1 (fr) 2006-03-29
US7405306B2 (en) 2008-07-29
US7235554B2 (en) 2007-06-26
JP4575670B2 (ja) 2010-11-04
CA2481460A1 (en) 2003-10-09
BR0309018A (pt) 2005-02-01
EP1492792A2 (fr) 2005-01-05
HK1074632A1 (zh) 2005-11-18
ES2261940T3 (es) 2006-11-16
UA77273C2 (en) 2006-11-15
EA007219B1 (ru) 2006-08-25
JP2010248221A (ja) 2010-11-04
NZ535741A (en) 2007-03-30
DE60304327D1 (de) 2006-05-18
WO2003082874A2 (fr) 2003-10-09
JP2005527566A (ja) 2005-09-15
CN1656099A (zh) 2005-08-17
DK1492792T3 (da) 2006-08-14
DE60304327T2 (de) 2006-12-28
JP5277208B2 (ja) 2013-08-28
HK1102371A1 (en) 2007-11-16
US20070219202A1 (en) 2007-09-20
CN100406459C (zh) 2008-07-30
MXPA04009635A (es) 2005-07-13
PT1492792E (pt) 2006-08-31
MEP23708A (en) 2010-06-10
IS2483B (is) 2008-12-15
FR2838124B1 (fr) 2004-05-28
US7323467B2 (en) 2008-01-29
ZA200407945B (en) 2005-11-30
CN100543016C (zh) 2009-09-23
US20050124615A1 (en) 2005-06-09
CA2481460C (en) 2011-02-15
US20080076775A1 (en) 2008-03-27
CY1104998T1 (el) 2009-11-04
NO20044153L (no) 2004-12-27
HRP20040911A2 (en) 2004-12-31
US20080255129A1 (en) 2008-10-16
HRP20040911B1 (en) 2012-11-30
WO2003082874A3 (fr) 2004-04-01
PL372617A1 (en) 2005-07-25
CN1970538A (zh) 2007-05-30
EA200401146A1 (ru) 2005-06-30
ME00081B (me) 2010-10-10
AU2003240930A1 (en) 2003-10-13
FR2838124A1 (fr) 2003-10-10
ATE321763T1 (de) 2006-04-15
IL164257A (en) 2009-11-18
IL164257A0 (en) 2005-12-18
RS86904A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
JP5277208B2 (ja) 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
KR101165483B1 (ko) 2H- 또는 3H-벤조[e]인다졸-1-일 카르바메이트 유도체, 이들의 제조 방법 및 치료 용도
KR100936565B1 (ko) 3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-카르복사미드 유도체, 그의 제법 및 치료 용도
JP2008536901A (ja) 1H−ピリミド[4,5−b]インドール誘導体、これらの調製及び治療的使用
HK1074632B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
HK1102371B (en) Intermediate compound of 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives
MXPA06009859A (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140810

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140810

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000